1. |
|
|
2. |
|
|
3. |
|
|
4. |
- Almer, Sven
(author)
-
Novel Strategies in the Thiopurine Treatment of Inflammatory Bowel Disease
- 2010
-
In: Nucleosides, Nucleotides & Nucleic Acids. - : Taylor and Francis. - 1525-7770 .- 1532-2335. ; 29:04-Jun, s. 267-277
-
Journal article (peer-reviewed)abstract
- Thiopurine drugs are widely used as immunomodulatory and corticosteroid-sparing agents in inflammatory bowel disease. Despite being old drugs, a renewed research and clinical interest in their application has emerged during the last decade. The application of pharmacogenetic insights and metabolic monitoring, together with treatment strategies in combination with anti-TNF-antibodies and possibilities to modulate their metabolism, has paved the way to a omoderno use of the thiopurines. These aspects are briefly overviewed herein.
|
|
5. |
- Andersen, Gorm, et al.
(author)
-
Catabolism of pyrimidines in yeast: A tool to understand degradation of anticancer drugs
- 2006
-
In: Nucleosides, Nucleotides & Nucleic Acids. - : Informa UK Limited. - 1525-7770 .- 1532-2335. ; 25:9-11, s. 991-996
-
Journal article (peer-reviewed)abstract
- The pyrimidine catabolic pathway is of crucial importance in cancer patients because it is involved in degradation of several chemotherapeutic drugs, such as 5-fluorouracil; it also is important in plants, unicellular eukaryotes, and bacteria for the degradation of pyrimidine-based biocides/antibiotics. During the last decade we have developed a yeast species, Saccharomyces kluyveri, as a model and tool to study the genes and enzymes of the pyrimidine catabolic pathway. In this report, we studied degradation of uracil and its putative degradation products in 38 yeasts and showed that this pathway was present in the ancient yeasts but was lost approximately 100 million years ago in the S. cerevisiae lineage.
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
- Björnberg, Olof, et al.
(author)
-
Ribosylurea accumulates in yeast urc4 mutants
- 2010
-
In: Nucleosides, Nucleotides & Nucleic Acids. - : Informa UK Limited. - 1525-7770 .- 1532-2335. ; 29:4-6, s. 433-437
-
Journal article (peer-reviewed)abstract
- Yeast Saccharomyces (Lachancea) kluyveri urc4 mutants, unable to grow on uracil, biotransformed (14)C(2)-uracil into two labeled compounds, as detected by high performance liquid chromatography (HPLC). These two compounds could also be obtained following organic synthesis of ribosylurea. This finding demonstrates that in the URC pyrimidine degradation pathway, the opening of the uracil ring takes place when uracil is attached to the ribose moiety. Ribosylurea has not been reported in the cell metabolism before and the two observed compounds likely represent an equilibrium mixture of the pyranosyl and furanosyl forms.
|
|